Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Jun;21(6):655–659. doi: 10.1111/j.1365-2125.1986.tb05230.x

The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.

D Bach, R Blevins, N Kerner, M Rubenfire, D J Edwards
PMCID: PMC1400979  PMID: 3741715

Abstract

The effect of verapamil pre-treatment on the pharmacokinetics and metabolism of antipyrine was studied in eight healthy male volunteers. The oral clearance of antipyrine was decreased from 2.18 to 1.95 l h-1 (P less than 0.01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13.2 to 15.6 h (P less than 0.01). The urinary excretion of norantipyrine, 4-hydroxyantipyrine and 3-hydroxymethylantipyrine was decreased by 19.2%, 23.1% and 16.7% respectively (P less than 0.05) in the presence of verapamil. In addition, the rate constants for formation of each of these metabolites were significantly decreased by an average of approximately 30%. These results suggest that verapamil is capable of inhibiting oxidative metabolism, a finding which could be of clinical significance for drugs highly dependent upon pathways such as those inhibited in this study for elimination.

Full text

PDF
655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bax N. D., Lennard M. S., Tucker G. T. Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol. 1981 Dec;12(6):779–784. doi: 10.1111/j.1365-2125.1981.tb01306.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burnakis T. G., Seldon M., Czaplicki A. D. Increased serum theophylline concentrations secondary to oral verapamil. Clin Pharm. 1983 Sep-Oct;2(5):458–461. [PubMed] [Google Scholar]
  3. Conrad K. A., Byers J. M., 3rd, Finley P. R., Burnham L. Lidocaine elimination: effects of metoprolol and of propranolol. Clin Pharmacol Ther. 1983 Feb;33(2):133–138. doi: 10.1038/clpt.1983.20. [DOI] [PubMed] [Google Scholar]
  4. Conrad K. A., Nyman D. W. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther. 1980 Oct;28(4):463–467. doi: 10.1038/clpt.1980.189. [DOI] [PubMed] [Google Scholar]
  5. Cummings A. J., Martin B. K., Park G. S. Kinetic considerations relating to the accrual and elimination of drug metabolites. Br J Pharmacol Chemother. 1967 Feb;29(2):136–149. doi: 10.1111/j.1476-5381.1967.tb01947.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Daneshmend T. K., Roberts C. J. The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects. Br J Clin Pharmacol. 1982 Jun;13(6):817–820. doi: 10.1111/j.1365-2125.1982.tb01872.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Danhof M., van Zuilen A., Boeijinga J. K., Breimer D. D. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol. 1982;21(5):433–441. doi: 10.1007/BF00542332. [DOI] [PubMed] [Google Scholar]
  8. Eichelbaum M., Somogyi A. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. Eur J Clin Pharmacol. 1984;26(1):47–53. doi: 10.1007/BF00546708. [DOI] [PubMed] [Google Scholar]
  9. Freedman S. B., Richmond D. R., Ashley J. J., Kelly D. T. Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther. 1981 Nov;30(5):644–652. doi: 10.1038/clpt.1981.216. [DOI] [PubMed] [Google Scholar]
  10. Greenblatt D. J., Franke K., Huffman D. H. Impairment of antipyrine clearance in humans by propranolol. Circulation. 1978 Jun;57(6):1161–1164. doi: 10.1161/01.cir.57.6.1161. [DOI] [PubMed] [Google Scholar]
  11. Kates R. E., Keefe D. L., Schwartz J., Harapat S., Kirsten E. B., Harrison D. C. Verapamil disposition kinetics in chronic atrial fibrillation. Clin Pharmacol Ther. 1981 Jul;30(1):44–51. doi: 10.1038/clpt.1981.125. [DOI] [PubMed] [Google Scholar]
  12. Kessler K. M., Humphries W. C., Jr, Black M., Spann J. F. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. Am Heart J. 1978 Nov;96(5):627–635. doi: 10.1016/0002-8703(78)90200-4. [DOI] [PubMed] [Google Scholar]
  13. Shand D. G., Hammill S. C., Aanonsen L., Pritchett E. L. Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther. 1981 Nov;30(5):701–706. doi: 10.1038/clpt.1981.223. [DOI] [PubMed] [Google Scholar]
  14. Slusher L. B., Vesell E. S. Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites. Clin Pharmacol Ther. 1984 May;35(5):568–575. doi: 10.1038/clpt.1984.79. [DOI] [PubMed] [Google Scholar]
  15. Wood A. J., Carr K., Vestal R. E., Belcher S., Wilkinson G. R., Shand D. G. Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol. 1978 Oct;6(4):345–350. doi: 10.1111/j.1365-2125.1978.tb00862.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES